Welcome to our dedicated page for G1 Therapeutics news (Ticker: GTHX), a resource for investors and traders seeking the latest updates and insights on G1 Therapeutics stock.
G1 Therapeutics, Inc. (Nasdaq: GTHX) is a commercial-stage oncology biopharmaceutical company committed to developing next-generation therapies to improve the lives of cancer patients. The company is based in Research Triangle Park, N.C., and leverages its proprietary kinase drug discovery platform to advance a pipeline of innovative compounds. G1's flagship product, COSELA® (trilaciclib), has been approved by the FDA to decrease the incidence of chemotherapy-induced myelosuppression in patients with extensive-stage small cell lung cancer (ES-SCLC).
In addition to COSELA, G1 Therapeutics is actively developing and evaluating trilaciclib in combination with other anti-cancer therapies. One notable project is the global, multi-center, randomized, placebo-controlled Phase 3 trial known as PRESERVE 2, which investigates trilaciclib in patients with metastatic triple-negative breast cancer (mTNBC). Preliminary results have shown promising survival benefits, indicating trilaciclib’s potential to protect bone marrow and enhance patient outcomes during cytotoxic therapy.
The company also engages in strategic partnerships to broaden its impact. For instance, G1 Therapeutics has entered agreements with companies like Pepper Bio and Jupiter Bioventures to advance the clinical development and commercialization of lerociclib, another promising CDK4/6 inhibitor. These collaborations aim to explore lerociclib's efficacy in treating various cancers, including HCC and radioprotection uses.
On the financial front, G1 Therapeutics reported revenues of $82.5 million for the full year 2023, reflecting significant growth from $51.3 million in the previous year. The company's ongoing commitment to innovation and strategic collaborations underscores its role as a key player in oncology therapeutics.
For more information, visit G1 Therapeutics and follow them on Twitter and LinkedIn.
G1 Therapeutics has appointed Andrew Perry as the new Chief Commercial Officer, succeeding Soma Gupta. This change is part of the company's strategy to enhance the launch of COSELA™ (trilaciclib) in extensive-stage small cell lung cancer. Perry brings nearly 25 years of experience in product commercialization and has a strong background in oncology. Additionally, the company has granted Perry a stock option to purchase 300,000 shares, enhancing his commitment to G1 Therapeutics. This leadership transition aims to further optimize the operational execution and commercial success of its product line.
G1 Therapeutics (GTHX) will host a webcast and conference call on August 4, 2021, at 4:30 p.m. ET to discuss its second-quarter 2021 corporate and financial update. The call can be accessed via phone or through their Events & Presentations page. G1 Therapeutics is focused on developing therapies for cancer, including their product, COSELA™ (trilaciclib), with ongoing clinical evaluations in various solid tumors. The company is based in Research Triangle Park, N.C.
G1 Therapeutics, Inc. (GTHX) announced that the FDA granted Fast Track designation for COSELA™ (trilaciclib) in treating locally advanced or metastatic triple negative breast cancer (TNBC). This designation is aimed at expediting drug development and regulatory review, potentially leading to earlier patient access. COSELA is being tested in a pivotal Phase 3 trial (PRESERVE 2) alongside chemotherapy for TNBC, a notably aggressive cancer representing 15-20% of breast cancer cases. The company aims to enhance patient outcomes with this innovative treatment.
G1 Therapeutics (GTHX) announced the grant of inducement stock options for 80,400 shares to eight new employees under its 2021 Inducement Equity Incentive Plan. This grant adheres to Nasdaq Listing Rule 5635(c)(4) and incentivizes new hires. Options are priced at $22.47, reflecting the closing price on July 1, 2021, and vest over four years. G1 focuses on oncology, including the commercialization of COSELA™ and a range of clinical developments targeting various solid tumors.
G1 Therapeutics (GTHX) announced the appointment of Alicia Secor to its Board of Directors, enhancing its strategic leadership. With over 30 years in the life sciences sector, Secor has a proven history of guiding companies through product commercialization. Currently CEO of Atalanta Therapeutics, she emphasizes her commitment to maximizing the value of COSELA™ and improving patient access. CEO Jack Bailey highlighted Secor’s experience and vision as crucial for G1’s future growth. Secor's prior roles include leadership positions at Juniper Pharmaceuticals and Genzyme.
G1 Therapeutics, a commercial-stage oncology company, announced that CEO Jack Bailey will participate in the 2021 Raymond James Human Health Innovation Conference on June 22 at 9:20 AM EDT. The virtual event will include a fireside chat, accessible via a live webcast on G1's website. G1 Therapeutics specializes in developing therapies for cancer patients, including their first product, COSELA™ (trilaciclib), which is being evaluated in various solid tumors like colorectal, breast, lung, and bladder cancers. For more details, visit their website.
G1 Therapeutics has initiated PRESERVE 3, a Phase 2 study to evaluate COSELA (trilaciclib) combined with platinum-based chemotherapy and avelumab for treating metastatic urothelial carcinoma (mUC). The randomized trial aims to enroll 90 patients, assessing the safety, efficacy, and myeloprotection of COSELA. Initial results are expected in late 2022, with endpoints focused on progression-free survival and overall survival. The study addresses the stagnant five-year survival rate for mUC, highlighting a significant unmet need in this area.
G1 Therapeutics (GTHX) announced the grant of inducement stock options for a total of 44,200 shares to five new employees as part of its 2021 Inducement Equity Incentive Plan. These options are exercisable at $21.93 per share, the closing price on the grant date of June 1, 2021. Each option vests over four years, with 25% vesting after the first year. The plan is designed to attract new talent by granting equity awards to individuals who were not previously employed by G1, in compliance with Nasdaq rules.
G1 Therapeutics, Inc. (GTHX) reported positive results from its Phase 1 study of rintodestrant, an oral selective estrogen receptor degrader, in combination with palbociclib for ER+/HER2- advanced breast cancer. The combination treatment demonstrated a significant increase in the clinical benefit rate, rising from 30% with rintodestrant alone to 60% with the combination. The treatment was well tolerated, with no serious adverse events reported. The study suggests potential effectiveness, especially in patients with ESR1 variants, further warranting clinical evaluation.
G1 Therapeutics (GTHX) presented positive results from analyses of COSELA (trilaciclib) during the ASCO annual meeting, focusing on its immune effects in extensive-stage small cell lung cancer (ES-SCLC) patients. Analyses from two Phase 2 trials revealed that patients receiving COSELA showed significantly greater peripheral T-cell clonal expansion compared to placebo recipients. Results indicate a potential link between peripheral clonal expansion and clinical response. The company also highlighted ongoing Phase 3 trials for COSELA in triple-negative breast cancer.
FAQ
What is the current stock price of G1 Therapeutics (GTHX)?
What is the market cap of G1 Therapeutics (GTHX)?
What does G1 Therapeutics, Inc. specialize in?
What is COSELA® (trilaciclib)?
What is the PRESERVE 2 trial?
Where is G1 Therapeutics, Inc. located?
Who are G1 Therapeutics' key partners?
What recent financial achievements has G1 Therapeutics reported?
What is lerociclib?
How can I get more information about G1 Therapeutics?
What types of cancer are G1 Therapeutics’ therapies targeting?
What are G1 Therapeutics’ future goals?
